TheraRadar
Clinical-Stage Companies / Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited

Pre-Approval PRO BETA
54
Total Trials
26
Phase 3
18
Phase 2
9
Recruiting
564
Score

Pipeline by Phase

Phase 3
26
Phase 2
18
Phase 1
5

Therapeutic Focus

Acne Vulgaris Plaque Psoriasis Active Psoriatic Arthritis Dry Eye Disease Keratoconjunctivitis Sicca

Clinical Trials (54)

NCT03897075 Phase 3 COMPLETED

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Started: 5/13/2021

NCT06611163 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Started: 3/21/2025

NCT04314531 Phase 3 ACTIVE NOT RECRUITING

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Started: 7/1/2020

NCT04991116 Phase 3 ACTIVE NOT RECRUITING

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Started: 6/30/2022

NCT04314544 Phase 3 COMPLETED

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Started: 7/1/2020

NCT05022004 Phase 3 COMPLETED

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Started: 12/20/2021

NCT03897088 Phase 3 COMPLETED

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Started: 3/29/2019

NCT02688556 Phase 3 COMPLETED

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Started: 2/1/2016

NCT01722331 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

Started: 12/6/2012

NCT01729754 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

Started: 2/5/2013

NCT01936688 Phase 3 WITHDRAWN

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Started: 9/1/2013

NCT02534896 Phase 3 TERMINATED

To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis

Started: 11/1/2015

NCT01408082 Phase 3 COMPLETED

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

Started: 10/1/2011

NCT02845674 Phase 3 COMPLETED

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Started: 7/29/2016

NCT01543490 Phase 3 COMPLETED

Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects

Started: 3/30/2018

NCT03192150 Phase 3 COMPLETED

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

Started: 1/3/2018

NCT01576952 Phase 3 COMPLETED

Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects

Started: 7/1/2012

NCT01808547 Phase 3 COMPLETED

Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

Started: 5/1/2013

NCT03192137 Phase 3 COMPLETED

Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

Started: 1/30/2018

NCT03927443 Phase 3 WITHDRAWN

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

Started: 6/10/2019

NCT03528577 Phase 3 COMPLETED

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

Started: 9/22/2018

NCT01406717 Phase 3 COMPLETED

Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Started: 3/1/2013

NCT01753102 Phase 3 TERMINATED

Efficacy and Safety Of Spil's Estradiol Vaginal Tablet

Started: 11/6/2012

NCT07282743 Phase 2 RECRUITING

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Started: 1/20/2026

NCT05422911 Phase 2 RECRUITING

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Started: 8/31/2022

NCT03997786 Phase 2 ACTIVE NOT RECRUITING

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Started: 1/15/2020

NCT04566666 Phase 2 COMPLETED

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Started: 3/25/2021

NCT04684485 Phase 2 COMPLETED

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

Started: 7/30/2021

NCT03552276 Phase 2 COMPLETED

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Started: 7/11/2018

NCT04506463 Phase 2 COMPLETED

Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

Started: 12/22/2020

NCT02980692 Phase 2 COMPLETED

Efficacy and Safety Study of SUNPG1623

Started: 4/19/2017

NCT02254265 Phase 2 COMPLETED

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Started: 9/1/2014

NCT02737332 Phase 2 COMPLETED

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Started: 3/21/2016

NCT01387464 Phase 2 COMPLETED

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

Started: 7/1/2011

NCT01478555 Phase 2 WITHDRAWN

A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease

Started: 1/1/2018

NCT02962284 Phase 2 COMPLETED

One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™

Started: 11/1/2016

NCT02980705 Phase 2 TERMINATED

Efficacy and Safety Study of SUNPG1622

Started: 11/6/2017

NCT03298581 Phase 2 WITHDRAWN

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis

Started: 1/1/2017

NCT03245385 Phase 2 TERMINATED

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

Started: 7/24/2017

NCT07385547 Phase 1 RECRUITING

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

Started: 2/25/2026

NCT07729579 Phase 1 RECRUITING

An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

Started: 8/4/2026

NCT01190878 Phase 1 COMPLETED

Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

Started: 8/1/2010

NCT01948024 Phase 1 COMPLETED

Bio-equivalence Study Between SAPHRIS and Asenapine

Started: 7/1/2013

NCT01699022 Phase 1 COMPLETED

Pharmacokinetic and Pharmacodynamic Study of Cyclofem

Started: 6/1/2010

NCT06425900 Phase 4 ACTIVE NOT RECRUITING

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Started: 7/1/2024

NCT06415305 Phase 4 COMPLETED

A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

Started: 9/1/2023

NCT06336603 Phase 4 COMPLETED

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Started: 11/15/2023

NCT06336629 Phase 4 COMPLETED

A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

Started: 11/15/2023

NCT06415279 Phase 4 COMPLETED

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

Started: 2/14/2024

NCT06415292 Phase 4 COMPLETED

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

Started: 11/27/2023

NCT04357795 Phase 4 COMPLETED

Effect of Cequa™ in Subjects With Dry Eye Disease

Started: 6/29/2020

NCT03718299 Phase 4 COMPLETED

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Started: 7/16/2019

NCT03212963 Phase 4 TERMINATED

Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%

Started: 3/21/2017

NCT02457520 Phase 4 COMPLETED

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

Started: 1/21/2015

Drug Candidates

Tildrakizumab Tildrakizumab 100 mg GL0034 Dose Level 1 GL0034 Dose Level 2 GL0034 Dose Level 3 GL0034 Dose Level 4 GL0034 Dose Level 5 GL0034 Dose Level 6 GL0034 TILD
Activity Status: Active
Last Trial Started: 8/4/2026
Last Trial Ended: 12/22/2025
Trials (12 months): 3
Completed Trials: 36
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.